Alercell Launches Website Dedicated to New Cancer Detection Tests
Alercell has launched a new website—Lena Diagnostics—dedicated to proprietary tests focused on early detection of cancer and leukemia.
Alercell has launched a new website—Lena Diagnostics—dedicated to proprietary tests focused on early detection of cancer and leukemia.
PixCell’s HemoScreen may be used to monitor pathological blood samples, improving treatment process for hematological patients.
Sight Diagnostics’ patented Olo analyzer digitizes blood into images to perform the most common blood test in minutes, using just two drops of blood.
The study demonstrates the potential for more impactful, dynamic therapy development and applications for those with acute myeloid leukemia.
Read MoreThe license encompasses both a novel method and bioinformatic tools that combine to improve the level of detection in NGS, allowing for the identification of ultrarare gene variants.
Read MoreUsing the kit, clinicians can accurately and reproducibly monitor residual disease in patients with chronic myeloid leukemia, even at low levels.
Read MoreClearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.
Read MoreDroplet digital PCR can provide a more accurate assessment of low levels of BCR-ABL mRNA than quantitative real-time PCR.
Read MoreNew applications include customizable QIAact target enrichment panels for next-generation sequencing of more than 13 hereditary disease groups.
Read MoreSeraCare Life Sciences has expanded its suite of clinical genomics development, validation, and quality control tools with the launch of Seraseq myeloid DNA and myeloid RNA fusion reference materials.
Read MoreBio-Rad Laboratories has introduced the QXDx BCR-ABL %IS kit, a CE-marked digital polymerase chain reaction test that can monitor the molecular response to therapy of patients with chronic myeloid leukemia.
Read MoreAgency allows marketing of the QuantideX qPCR BCR-ABL IS kit, the first nucleic acid-based quantitation test for use during treatment of rare leukemia.
Read MoreAfter its ASH 2014 debut, the RainDance HemOnc Consortium, an international panel of clinical research experts, will focus on developing assays for liquid biopsy research of myeloid disorders.
Read MoreA new collaboration plans to provide genomic profiling and information for patients that have been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas, and myeloproliferative and myelodysplastic diseases.
Read MoreThe test has been shown to offer sensitivity for the detection of residual cancer cells in marrow or blood.
Read MoreWith so many types of lymphoma, there’s a wide range of corresponding lab tests to detect their presence in patients. Here, CLP takes a look at testing for the most common type of lymphoma (diffuse large B-cell
Read More